secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001564590-22-037382
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics reports Q3 2022 net loss of $8.3M; cash at $126M
-------------------------------------------------------------------

- Net loss of $8.3M in Q3 2022 vs. $7.3M in Q3 2021; R&D expenses rose to $5.8M.
- Cash, cash equivalents, and investments totaled $126M as of Sept 30, 2022.
- Phase 2 CANAL trial for chronic cough in IPF met primary endpoint with 75.1% reduction in cough frequency (placebo-adjusted 52.5%, p<0.0001).
- Phase 2b/3 PRISM trial for prurigo nodularis open-label extension ongoing; end-of-phase 2 FDA meeting planned Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022037382/0001564590-22-037382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022037382/trvi-8k_20221110.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-037382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer